New Vaccines

Combining disease surveillance and vaccine evaluation to generate evidence that strengthens immunisation strategies, informs public health decision-making, and assesses cost-effectiveness.

Our group integrates global disease surveillance with vaccine evaluation to strengthen immunisation strategies worldwide. We work across Australia, Mongolia, Indonesia, Vietnam, Fiji and the broader Asia–Pacific region, as well as some countries in Africa. We partner with governments, research institutions, laboratories and international agencies.

The challenge

Despite major advances in vaccination, infectious diseases remain a significant cause of illness, hospitalisation and preventable death.

Countries face complex decisions around vaccine schedules, product selection and equitable access, particularly for vulnerable populations. In addition, climate change is accelerating the expansion of infectious diseases across the globe.

Our research

We combine disease and carriage surveillance, clinical trials, immunological research to generate real world evidence. Our work assesses vaccine effectiveness, optimises vaccination strategies, and evaluates cost-effectiveness to inform national and global immunisation policy. We also assess the impact of other risk factors such as air pollution on the burden of infectious diseases.

Future impact

By strengthening the evidence base for vaccination programs, we aim to reduce disease burden, improve health equity, and support sustainable immunisation strategies, especially in lower income countries, that protect current and future generations.